Research programme: MOSPD2 monoclonocal antibodies - Notable Labs
Alternative Names: Anti-MOSPD2 monoclonal antibodies; VB-600 monoclonal antibody seriesLatest Information Update: 28 Nov 2024
At a glance
- Originator VBL Therapeutics
- Developer Notable Labs
- Class Anti-inflammatories; Antirheumatics; Hepatoprotectants; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Inflammatory bowel diseases; Multiple sclerosis; Non-alcoholic steatohepatitis; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Israel (Parenteral)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Israel (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (Parenteral)